BackStryker Overview

Stryker EBIT

Latest ebit for SYK.TO: $4.9B, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$997.00M
↓ 3.11% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$4.91B
↑ 41.81% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Stryker (SYK.TO) FAQ

The latest EBIT for SYK.TO is $4.9B as of September 2026. That compares with $3.5B in the prior-year period — up 41.8% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Stryker's historical trend and sector peers before judging valuation or financial health.

Over the past year, SYK.TO's EBIT moved from $3.5B to $4.9B — a 41.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Stryker's operating scale or balance-sheet position.

Against Healthcare companies, SYK.TO currently prints $4.9B for EBIT, while the sector average sits near $1.9T. That is roughly 99.7% below the sector mean. Large gaps often invite a closer look at Stryker's growth, margins, and balance sheet.

A EBIT figure of $4.9B for SYK.TO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting SYK.TO's EBIT ($4.9B), review year-over-year change from $3.5B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers